Document is current
Any future updates will be listed below
-
Authors
Wu, Xiaojie
He, Jinjie
Wu, Junzhen
Liu, Wei
Xu, Yulong
Li, Yiming
Zhang, Jing https://orcid.org/0000-0003-2966-9149
Wang, Qinghua
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05694221 at ClinicalTrials.govDocuments that mention this clinical trial
Effect of Efsubaglutide Alfa on the Pharmacokinetics of Metformin and Digoxin in Healthy Participants
https://doi.org/10.1007/s40262-025-01541-0
-
Funding
Funding for this research was provided by:
Innogen Pharmaceutical Co. Ltd
- License Information
-
More Information
Article History
Accepted: 13 May 2025
First Online: 30 June 2025
Declarations
:
: Innogen Pharmaceutical Co. Ltd.
: Qinghua Wang is the founder of Innogen Pharmaceutical Co. Ltd. Yulong Xu is an employee of Innogen Pharmaceutical Co. Ltd. The remaining authors declare no competing interests.
: The study was approved by the relevant ethics committees and conducted in accordance with the principles of the Declaration of Helsinki and the International Council for Harmonisation guidelines for Good Clinical Practice (ICH-GCP).
: Data will be made available upon reasonable request, participant to the protection of research participants’ privacy.
: Jinjie He, Xiaojie Wu, and Yulong Xu drafted the manuscript. Jing Zhang, Xiaojie Wu, Jinjie He, Wei Liu, Junzhen Wu, and Yiming Li made important contributions to participants recruitment and safety evaluation. Jing Zhang, Xiaojie Wu, Yulong Xu, and Qinghua Wang reviewed and edited the manuscript.
